Anti-ige antibody to treat ocular allergies
CA 2445269 A1 · Owner: Novartis Ag · Inventors: Latour, Elisabeth; Lambrou, George N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of an anti-IgE antibody in the preparation of a topical ophthalmic composition for the treatment of an ocular allergic disorder and a method to treat ocular allergic disorders in a patient in need therefore, which method comprises the topical administration of an opthalmic composition comprising an anti-IgE antibody.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 2, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 2, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 2, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.